Analyst Price Targets — PTHS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 15, 2026 11:40 am | Jeff Jones | Oppenheimer | $66.00 | $27.69 | TheFly | Pelthos Therapeutics price target raised to $66 from $62 at Oppenheimer |
| February 26, 2026 12:52 am | — | Roth Capital | $55.00 | $23.00 | TheFly | Pelthos Therapeutics price target lowered to $55 from $57 at Roth Capital |
| January 26, 2026 1:22 pm | — | Oppenheimer | $60.00 | $24.75 | TheFly | Pelthos Therapeutics price target raised to $60 from $57 at Oppenheimer |
| December 3, 2025 1:13 pm | — | Lake Street | $50.00 | $27.38 | TheFly | Pelthos Therapeutics initiated with a Buy at Lake Street |
| December 3, 2025 11:11 am | — | H.C. Wainwright | $60.00 | $25.14 | TheFly | Pelthos Therapeutics initiated with a Buy at H.C. Wainwright |
| November 25, 2025 9:29 am | — | Roth Capital | $57.00 | $27.53 | TheFly | Pelthos Therapeutics initiated with a Buy at Roth Capital |
| September 2, 2025 10:18 am | — | UBS | $50.00 | $22.46 | TheFly | Pelthos Therapeutics initiated with an Outperform at Oppenheimer |
Latest News for PTHS
DURHAM, N.C., June 30, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, (“Pelthos”), today announced that the company was added as a member of the Russell 3000E™ Growth Benchmark, Russell Microcap®, and Russell Microcap® Growth Benchmark Indexes effective when the US market…
DURHAM, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, (“Pelthos”), today announced that CEO Scott Plesha will present at 11:05 am ET and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference on June 4, 2026 in New York.…
Pelthos Therapeutics NYSEAMERICAN: PTHS reported higher first-quarter revenue as prescriptions for its lead product, ZELSUVMI, continued to grow in the treatment's third full quarter since launch, executives said on the company's 2026 first-quarter earnings call.
Pelthos Therapeutics Inc. (PTHS) Q1 2026 Earnings Call Transcript
Pelthos Therapeutics Inc. (PTHS) came out with a quarterly loss of $3.09 per share versus the Zacks Consensus Estimate of a loss of $4. This compares to a loss of $3.2 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PTHS.
U.S. House Trading
No House trades found for PTHS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.